Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Media and Investors Resources
Press Release, 31 January 2024
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Press Release, 4 January 2024
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Press Release, 27 December 2023
Adhoc Press Release
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Press Release, 28 November 2023
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Press Release, 12 October 2023
Adhoc Press Release
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Kuros Interim Results, 2023
English version